..
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City
California
94404
U.S.A.
Phone:
800-GILEAD-5 or 650-574-3000
Fax:
650-522-5800
|
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
Key Contacts:
John C. Martin, PhD, Chairman and Chief Executive Officer
John F. Milligan, PhD, President and Chief Operating Officer
Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer
Kevin Young, Executive Vice President, Commercial Operations
Gregg Alton, Executive Vice President, Corporate and Medical Affairs
Kristen Metza, Senior Vice President, Human Resources
Robin Washington, Senior Vice President and Chief Financial Officer
Susan Hubbard, Vice President, Investor Relations
Amy Flood, Vice President, Public Affairs
Email:
Ownership:
Public
Web Site:
Gilead Sciences, Inc.
Employees:
4,000
Symbol: GILD
|
|
|
Company News |
Gilead Sciences, Inc. (GILD) to Present at the Wells Fargo Securities 2013 Healthcare Conference on Tuesday, June 18
6/18/2013 9:28:00 AM
More...
|
Gilead Sciences, Inc. (GILD) Announces Interim Phase 2 Data for Idelalisib Showing Response in Refractory Indolent Non-Hodgkin's Lymphoma
6/17/2013 9:25:03 AM
More...
|
AbbVie (ABBV): We Can Win Race Against Gilead Sciences, Inc. (GILD) for First New Hepatitis C Drugs
6/14/2013 7:58:14 AM
More...
|
Gilead Sciences, Inc. (GILD)'s Viread Reduces HIV Risk for Drug Users in Study
6/13/2013 7:36:08 AM
More...
|
Gilead Sciences, Inc. (GILD) to Present at the Goldman, Sachs & Co. 34th Annual Healthcare Conference on Tuesday, June 11
6/11/2013 6:46:39 AM
More...
|
Gilead Sciences, Inc. (GILD) Announces FDA Priority Review Designation for Sofosbuvir for the Treatment of Hepatitis C
6/10/2013 10:12:37 AM
More...
|
Gilead Sciences, Inc. (GILD) to Present at the Deutsche Bank (DB) 38th Annual Health Care Conference on Wednesday, May 29
5/29/2013 7:26:17 AM
More...
|
European Commission (EC) Approves Gilead Sciences, Inc. (GILD)'s Stribild as Single Tablet Regimen for HIV-1 Treatment
5/28/2013 8:37:23 AM
More...
|
European Medicines Agency Validates Gilead Sciences, Inc. (GILD)'s Marketing Application for Sofosbuvir for the Treatment of Hepatitis C
5/22/2013 11:16:30 AM
More...
|
Gilead Sciences, Inc. (GILD) to Present at the 2013 UBS Global Healthcare Conference on Monday, May 20
5/20/2013 7:01:23 AM
More...
|
|
|
|